A Collaborative Randomised Controlled Trial

PROTOCOL
February 2003

ISRCTN 47279827
SUMMARY

It is estimated that 350 adults develop severe, but potentially reversible respiratory failure in the UK every year. Whilst intensive care of these patients is improving in specialist centres the mortality for the majority of patients has changed little in the last 20 years, and is approximately 70%. Extracorporeal membrane oxygenation (ECMO) is proven to result in improved outcome when compared to conventional ventilation in neonates with severe respiratory failure. ECMO provides gas exchange whilst the lungs are rested and allowed to recover, thereby reducing the effects of ventilator lung injury. A group at Glenfield Hospital has treated over 150 adults with ECMO since 1989. A detailed study of the first 50 patients revealed a hospital mortality of 34% for patients with a mean PaO2/FIO2 ratio of 65 mmHg and Murray score of 3.4. ECMO therefore seems a potentially promising therapy. It is now necessary to perform a randomised controlled trial (RCT) of ECMO compared to the current accepted intensive care treatment. An RCT would determine if this apparent reduction in mortality is a real phenomenon or merely an artifact caused by use of historical controls. If this is a real treatment effect there are important implications for increasing survival from severe respiratory failure, and also for planning health service provision. We propose an RCT where adults (18-65 years) with severe, but potentially reversible, respiratory failure (Murray score > 3.0 or hypercapnea with pH < 7.2) are randomised for consideration of ECMO or continuing intensive care. A concurrent economic evaluation will also be performed to compare the costs and outcomes of both treatments. It is vital that this trial is performed now as clinical equipoise may soon be lost as worldwide experience with adult ECMO grows. It is also essential that the best treatment for these severely ill patients can be defined now so that rational treatment and health service planning decisions can be made in their best interests.

BACKGROUND

It is estimated that over 350 adult patients suffer from severe, but potentially reversible, respiratory failure in the UK each year. The mortality rate for such patients is very high and has only improved marginally in the majority of centres over the last 20 years. Current management uses intermittent positive pressure ventilation (IPPV). The airway pressures and oxygen concentrations required to maintain adequate blood gases are often very high in patients with severe respiratory failure, and this combination of barotrauma, volutrauma and oxygen toxicity can prevent lung recovery. An alternative treatment, extracorporeal membrane oxygenation (ECMO), uses cardio-pulmonary bypass technology to temporarily provide gas exchange to patients with severe, but potentially reversible, respiratory failure. During ECMO, ventilator settings can be reduced, and such ‘lung-rest’ allows the lungs to recover. There is currently no good evidence from randomised controlled trials (RCTs) to compare ECMO against conventional management for important clinical outcomes.

Patients are usually considered for ECMO when they have such severe disease that they continue to deteriorate despite maximal optimum ‘conventional’ treatment. For the purposes of this protocol, conventional will be defined as any treatment which relies on the patient’s lungs to provide gas exchange. Conventional treatment may therefore include inhaled nitric oxide and prone ventilation, as well as the more usual types of positive pressure ventilation. The use of ECMO to support neonatal patients with severe respiratory failure has been rigorously evaluated in an RCT. The neonatal ECMO RCT convincingly demonstrated the effectiveness of ECMO in improving patient survival without severe disability. Neonatal ECMO in the UK is now a supra-regional service receiving central funding. The use of ECMO as it is currently practised in older children, and adults is more controversial, and has yet to be evaluated in an RCT in the UK.
Previous studies

A review of the literature was carried out to identify all studies relevant to adult ECMO. Only two RCTs have been reported, both in the United States but they used such different approaches that they have not been combined as a formal meta-analysis. Each is detailed below followed by the recent non-experimental evidence.

An RCT of adult ECMO was conducted by the US National Institutes of Health (NIH), in the early days of extra-corporeal support in the 1970s. Survival in both groups was very poor (around 10%), and no difference was shown in survival between the conventional and ECMO treated groups. There were a number of important differences in the perfusion and ventilation techniques used during this trial compared to those used today. Firstly, veno-arterial (VA) rather than veno-venous (VV) perfusion was used, and this was thought to be responsible for the high incidence of pulmonary micro-thrombosis and fibrosis seen in the lungs of the ECMO patients (due to reduced pulmonary blood flow). Secondly, patients were anti-coagulated to such a degree that severe bleeding occurred. Thirdly, high pressure ventilation was continued during ECMO resulting in continued barotrauma and volutrauma. Finally, the mean duration of ventilation prior to ECMO in the NIH ECMO trial was over 9 days, whereas it is now well-recognised that after 7 days of high pressure ventilation with high fraction of inspired oxygen (FIO₂) the lungs only have limited powers of recovery.

More recently there has been an RCT of the related technique of extra-corporeal carbon dioxide removal (ECCO₂R). This showed no difference between ECCO₂R and conventional treatment. Again there were numerous differences in the clinical and perfusion protocols between this trial and those in widespread use in the majority of centres currently. Firstly, the experimental arm of the trial used low flow ECCO₂R in a group of patients who had severe lung disease, which warranted higher flow ECMO with full support of oxygenation and carbon-dioxide removal. This was demonstrated by the need to increase the airway pressure in the ECCO₂R group half-way through the study. The reliance on the patient’s lungs to provide oxygenation, especially at such high airway pressures, also eliminated any possibility for lung rest. Also, despite the involvement of one of the team in the 1970s NIH ECMO trial, in which VA ECMO was used with very small numbers in each centre (<5), the ECCO₂R programme in this trial was not well developed prior to the study (as the team had only provided ECCO₂R to sheep and one patient prior to starting the trial). The high incidence of bleeding and thrombotic complications reported in this study may attest to this inexperience. In addition, the conventional treatment used in the trial was Pressure Controlled Inverse Ratio Ventilation (PCIRV) using a computer controlled algorithm. The results of this treatment showed 44% survival compared to expected survivals of < 20% in other similar series of patients. Despite this, survival in the ECCO₂R group was the same as the ‘conventional’ group. The success of the PCIRV protocol in this study has led to the wide adoption of the technique within ‘conventional’ ventilatory management with survival of 66% for patients with moderate to severe respiratory failure (mean Murray score 2.8, mean PaO₂/FIO₂ 88 mmHg). Unfortunately no other authors have been able to duplicate the PCIRV results of Morris et al. for patients with severe progressive respiratory failure.

Because the two trials described above have little relevance to the ECMO regimens used in the majority of centres worldwide, the only relevant evidence consists of observational studies. By the nature of their design, the information they provide is potentially biased, and must therefore be viewed with caution.
Recent case series of patients with similar degrees of respiratory failure to the eligibility criteria for the second trial suggest survival rates without ECMO of 18% to 44% \cite{1, 10} compared to rates of up to 66% with high flow ECMO (including full support of oxygenation and lung rest), provided by experienced teams principally in the USA, UK and Germany \cite{9, 13, 14}.

In a cohort study of the first 50 adult patients to receive ECMO for respiratory support at Glenfield Hospital, Leicester, UK, patients had severe respiratory failure as shown by the mean pre-ECMO Murray Lung Injury Score of 3.4 (SD 0.5) and \( \text{PaO}_2 / \text{FiO}_2 \) ratio of 65 mmHg (SD 36.9). They were referred for ECMO with severe respiratory failure caused by either the Acute Respiratory Distress Syndrome (ARDS) or with pneumonia. The overall survival rate was 66% \cite{9}.

For the reasons outlined above, it is impossible to reach firm conclusions from the above experimental and observational data regarding the clinical effectiveness or cost-effectiveness of VV high flow ECMO for respiratory failure in adults. The recent evidence from observational studies does, however, suggest that ECMO could potentially be a highly useful treatment in these patients. The case selection and treatment protocols used during ECMO are now well defined by the international Extracorporeal Life Support Organization (ELSO), and the only team using ECMO in adults consistently in the UK has built up clinical expertise \cite{9}.

It is not possible to further define the safety and efficacy of ECMO as a treatment without a rigorous trial. The procedure has received a Cii categorisation (safety and/ or efficacy not yet fully established; procedure requires a fully controlled evaluation) from the Safety and Efficacy Register of the New Intervventional Procedures of the Medical Royal Colleges (SERNIP). Additionally a situation of equipoise currently exists, whereby clinicians can see the potential benefits of ECMO, but do not have enough evidence to make an informed choice as to the best treatment for their patient. A well designed randomised controlled trial is thus urgently needed.
DESIGN AND METHODOLOGY

Design

The most scientifically rigorous design is that of an RCT. The design will be similar to the highly successful UK neonatal ECMO RCT suitably adapted for the adult population. The procedures are illustrated schematically in the Figure 1 below, and detailed in the text.

Primary hypotheses:

The primary hypotheses is that, for patients with severe, but potentially reversible, respiratory failure, ECMO:
(a) Will increase the rate of survival without severe disability by six months post-randomisation.
(b) Will be cost effective from the viewpoints of the NHS and society, compared to conventional ventilatory support.

Inclusion Criteria:

(i) Centres:

(a) ECMO: This will be provided in the Glenfield Hospital, Leicester, which has 12 years of experience and is the only ELSO-recognised adult ECMO centre in the UK.

(b) Conventional treatment centres (CTC): These are centres acknowledged by Critical Care Network leads (where established) to provide an appropriately high standard of conventional care for ECMO-eligible patients or by this protocol, as units which treat >350 patients per year, and can provide pressure controlled ventilation and veno-venous haemofiltration.

(c) Referral hospitals (RH): In addition to the centres described under (b) above, patients meeting ECMO entry criteria may be entered into the trial from other hospitals, if these hospitals are prepared to transfer the patient to a designated CTC should the allocation be to conventional management.

ii) Patients:

Adult patients (18-65 years) with severe, but potentially reversible respiratory failure. Severe respiratory failure will be defined as a Murray score (appendix 1) >3.0, or uncompensated hypercapnoea with a pH <7.20. The Murray score must be calculated using all 4 parameters (PaO$_2$/FIO$_2$, PEEP, Lung compliance and Chest X-ray appearance). The Murray score of 3.0 is a MINIMUM entry criterion. Since patients may deteriorate quickly and conventional treatment must be optimised prior to referral into the trial, intensivists will also have the option to discuss registration of the patient for the trial as soon as the Murray score exceeds 2.5. If the patient then continues to deteriorate, prior identification of available beds, and discussion of the trial with the relatives, if relatives are available, will allow rapid randomisation and trial entry.
Exclusion Criteria Prior to Trial Entry:

- Duration of high pressure and/or high FIO$_2$ ventilation > 7 days.$^{13}$
- Intra-cranial bleeding.
- Any other contra-indication to limited heparinisation.
- Patients who are moribund and have any contra-indication to continuation of active treatment.

Allocation of patients:

Selection bias at entry will be minimised by the procedures described below and shown schematically in Figure 1. Potentially eligible patients may be entered into the trial from any participating intensive care unit in the UK. The referring intensivist will contact a member of the clinical advisory team to confirm that the patient is eligible for the trial, and that beds for ECMO and conventional management are available. These beds will then be ‘held’ for at least two hours. If these conditions are met, the referring intensivist will discuss the trial with the patient’s relative(s), give written information, and ask for agreement to trial entry. The relative will be asked to sign the assent form indicating that he/she believes his/her relative would not object to taking part in the study. The intensivist will then speak to the advisory team and, if the assent procedure has been completed, the advisor will telephone the central randomisation service to register the identifying details, and to give information about key prognostic factors. Randomisation will then be to conventional management or to consideration of ECMO support.

Minimization criteria will be used to ensure a balance of key prognostic factors between groups using the following criteria:

- Type of centre (CTC or RH)
- Age (18-30, 31-45, 46-65)
- Hours of high pressure and/or high FIO$_2$ ventilation (0-48, 49-168)
- Mode of trial entry (i.e. hypoxic / hypercarbic)
- Diagnostic group (pneumonia, obstetric acute respiratory distress syndrome (ARDS), trauma including surgery within previous 24 hours, other ARDS, and other)
- Numbers of organs failed 1-2 or 3 or more, failure being defined as an individual SOFA score for that organ of \( \geq 2 \) $^{17,18}$

If a patient is referred into the trial when there is no ICU or ECMO bed available that patient will not be entered. If beds become available subsequently, the patient is still suitable and the referring intensivist still wants to enter the patient then they will be randomised in the normal fashion. The fact that these patients were referred but were unable to be entered will be recorded.
**Figure 1: organisation of the trial**

**Potentially eligible patients**

(In CTC\(^1\), or RH\(^2\) prepared to refer to CTC or ECMO\(^3\) centre)

- severe, but potentially reversible respiratory failure:
  - Murray score $>2.5$
  - or
  - uncompensated hypercapnoea with a pH $<7.20$
- aged 18-65 years
- duration of high pressure and/or high FIO\(_2\) ventilation $<7$ days
- no intra-cranial bleeding
- no contra-indication to limited heparinisation
- no contra-indication to continuation of active treatment

**Registration**

Referring intensivist telephones clinical advisory team

- confirm that the patient is potentially eligible for trial
- confirm beds available (held for at least 2 hours) for
  - ECMO
  - and
  - conventional management in CTC

**Randomisation**

- potentially eligible patient becomes eligible (i.e. Murray score $\geq 3$)
- Assent procedure completed.
- **referring intensivist telephones clinical advisory team**
- provides details or identification and prognostic factors
- clinical advisor ‘phones independent central randomisation service for random allocation
- clinical advisor ‘phones referring intensivist
  - reveals allocation
- consideration of ECMO ECMO Centre
- continued conventional treatment in CTC
- If necessary arranges collection of patient
  - from CTC or RH to ECMO, or
  - from RH to CTC

---

\(^1\) CTC = conventional treatment centre is an Intensive Care Unit providing ‘optimal’ conventional intensive care in the trial

\(^2\) RH = referral hospital is a hospital providing high dependency/intensive care, but prepared for patients in trial to be transferred to CTC or ECMO centre (depending on random allocation)

\(^3\) ECMO = ECMO centre in Glenfield Hospital, Leicester. Adult ECMO will not be available outside the trial
Referrals for trial entry from hospitals not registered as trial centres:

During the study period ECMO will not be offered outside the framework of the trial. If, exceptionally, a hospital from outside the study wishes to refer a patient, the transport team from the ECMO centre will go to the hospital and assess the patient. If the patient is suitable then they will call the central randomisation service and the patient will be randomised in the normal fashion. If the patient draws conventional treatment the ECMO team will transport the patient to the nearest available CTC, and if selected for ECMO they will transport the patient back to Glenfield hospital.

Interventions:

1. Conventional Management
Patients randomised to conventional ventilatory support will receive the intensive care provided as standard in one of a number of participating CTCs. This may occasionally involve transfer (see Transport, below) from an RH. Conventional ventilatory support can include any treatment modality thought appropriate by the patient’s intensivist (excluding ECMO). Intensivists will have full discretion to treat patients as they think appropriate. It will be recommended that intensivists adopt the low volume ventilation strategy. Adherence to this strategy is defined for the purposes of CESAR as a plateau pressure <30 cm H₂O (or if plateau pressure is not measured the peak inspiratory pressure). This will usually mean a tidal volume of 4-8ml/ kg body weight as defined in the low tidal volume ventilation strategy according to the ARDS Network group 19.

Each CTC will produce their own statement of the general philosophy of treatment. This will be based on a pro-forma, which will detail their approach to ventilation, nutrition, antibiotics and other treatment issues. This pro-forma will also collect basic data regarding the size of unit, number of staff, cases treated per year etc.

2. ECMO
Patients randomised to ECMO will be transferred (see Transport, below) to the ECMO centre for consideration of ECMO support. During the trial adult ECMO will only be available as part of the trial. There will be no crossover to ECMO for patients allocated to conventional management. ECMO will be provided according to published Glenfield Hospital treatment protocols 9. This protocol is very similar to those used in other ELSO recognised Adult ECMO centres 14, and is summarised below:

Veno-venous ECMO via percutaneous cannulation is used if the patient's haemodynamic status is sufficiently stable to make cardiac assist (via veno-arterial access) unnecessary. Blood is drained from the right atrium through a cannula introduced via the right jugular or femoral veins, and is returned via the contra-lateral femoral vein. Circuits are designed to allow full support of gas exchange i.e. blood flow of 120 ml/ kg/ min. One or two (depending on body weight) Medos Hi-Lite 7000LT poly-methyl pentene lungs with heat exchangers are arranged in parallel with counter current gas flow, 100% oxygen is used as the sweep gas. Stockert (Sorin Biomedical) roller pumps with bladder box servo control or venous pressure servo-regulation are used. Blood raceway tubing is Tygon S-65-HL (Norton Performance Plastics). Normothermia is maintained. The circuit and patient are managed 24 hours per day by a trained “ECMO Specialist” capable of performing surveillance and emergency repairs to the circuit.
During ECMO, ventilator settings are gradually reduced to allow lung rest, i.e. peak inspiratory pressure 20 cm H$_2$O, end expiratory pressure 10 cm H$_2$O, rate 10 breaths per minute and FIO$_2$ 30%.

Anticoagulation is maintained with heparin to keep the activated clotting time (ACT) between 160 and 220 seconds. Patients are fed enterally or parenterally into the circuit, as indicated. Invasive procedures are avoided to reduce the risk of haemorrhage, and therefore any additional venous access necessary e.g. for haemofiltration, is achieved via the circuit. Patients are diuresed to dry weight. Haemoglobin concentrations are maintained at 14g/ dl, and platelet counts are kept >100,000 ml. Patients are weaned from ECMO and decannulated when chest X-ray appearance and lung compliance have improved, and adequate gas exchange without excessive ventilation (peak pressure less than 30 cmH$_2$O, and FIO$_2$ less than 60%) can be demonstrated during a ‘trial-off’ ECMO.

Patients developing liver failure either during or after ECMO (defined as a serum bilirubin >200 uMol/L) are supported with MARS (Teraklin GMBH, Rostock, Germany).

If the patient’s condition alters such that ECMO is no longer possible or appropriate then ECMO will not be initiated. However such a patient’s outcome will be analysed as part of the ECMO group (intention to treat).

3. Transport

Patients who are in a designated CTC will not need to be transported if they are randomised to conventional management. All other trial patients will need transport, which will be provided by a team from the ECMO centre. If the transport team decides that it is not safe to move the patient then s/ he will remain in the original unit until they are safe to transfer, recover or die. Such outcomes will also be analysed as part of the treatment option to which the patient was randomised i.e. analysis is by intention to treat.

Outcome measures

Primary:

Death or severe disability at six months (defined as death by 6 months or before discharge from hospital at any time to end of data collection, or answering EQ5D first two questions as ‘confined to bed' and ‘unable to wash or dress yourself').

Secondary:

I) Hospital Indices: duration of ventilation, use of high frequency/ oscillation/ jet ventilation, use of nitric oxide, prone positioning, use of steroids, length of ICU stay, length of hospital stay. Some data will be recorded daily (see “Economic issues”, below). For ECMO patients only, data will be collected on mode (VV/ VA), duration of ECMO, blood flow and sweep flow.

II) Health status 6 months after randomisation. This will include activities of daily living, quality of life, respiratory symptoms, cognitive psychological state and lung function. Where applicable carer strain will also be assessed.

III) Surviving patients will be asked to give agreement for information to be held by the General Register Office. If appropriate, further funding may be requested later for longer-term follow-up including lung function tests.
**Six month follow-up**

Assessment of the outcome at the 6 month follow-up will be performed by trained researchers who will interview and examine patients in their homes. Patients and their relatives will be instructed not to reveal which treatment was used. Patients will wear a special scarf to cover the neck, masking the presence or absence of cannulation wounds. The assessment will include a generic measure of health status (SF36) and quality of life (Euroqol EQ5D) respiratory related quality of life (St George’s hospital respiratory questionnaire) and cognitive function (Mini-mental state examination). The interview will also include specific questions on sleep (from the Functional limitation profile). Lung function will be assessed by spirometry and height measured to derive normal values. Where applicable, effects on the carer will be measured using the carer strain index. If a home visit is unacceptable patients are offered a telephone interview or postal questionnaire.

Information on severe disability (a primary outcome) will be obtained from the first two questions of EQ5D. For those too ill or unwilling to be assessed this information will be sought from a carer, whether the patient is at home or in an institution.

**Longer term follow-up**

Further follow up will be the subject of a separate protocol. So that the study organisers do not lose contact with patients should they move addresses, and also to follow up on health status, patients are being asked to give their agreement for their addresses to be sent to the NHS Central Register.

**Economic issues**

The primary objective of the economic evaluation is to assess incremental cost-effectiveness of ECMO in terms of additional survival with and without disability at six months post-randomisation. This will be done by determining the costs to health services and households, assessing cost-effectiveness from the viewpoint of the NHS and also from the societal viewpoint. The overall approach will be to describe the care received by patients in both arms of the trial, identifying use of health services with potentially important costs or changes in household resources.

The trial will assess the cost of treatment to the health and social services and to patients and their families in each treatment group. An incremental cost-effectiveness ratio will be calculated and compared to that for similar life-extending treatments. Information for the costs of inpatient and domiciliary care will be collected using methods adapted from the neonatal ECMO Trial.

Costs of care will be estimated by recording use of key health care services as part of the data set for each person in the trial, and separately estimating costs associated with each item of health care use. Service use will be measured as daily level of intensive care support, until discharge to an ordinary ward. Subsequent health care costs will be based on days of inpatient care, and use of transport, outpatient and primary care services.

Societal costs will be estimated for this trial as the net total costs to health services and to patients. Societal costs of illness can also include the costs borne by relatives and friends of visiting, supporting and caring for the patient. It is likely that visiting costs will differ between trial arms. Literature review found no studies of visiting costs for adult patients. A pilot study conducted outside the CESAR trial has established a survey method for measuring costs and will be conducted in a sub-sample of ICUs taking part in the trial and willing to do the additional research, in order to describe typical visiting costs for patients in ECMO and conventional centres.
To estimate levels of intensive care, data will be collected within the trial about the nature and duration of organ system support for individual patients. Data will be collected at the same time as the trial from participating intensive care centres and the ECMO centre to estimate costs of each level of care using a standard methodology\textsuperscript{25,26}. Health care service use after discharge will be derived from a questionnaire to patients at 6 months. Patients agreeing to participate will be invited to complete a simple diary as a memory aid to assist completion of the 6-month questionnaire. Household costs will be determined according to any changes the patients may have experienced in household circumstances (including major costs related to the illness and changes in economic activities).

Cost-effectiveness in terms of disability free survival and quality-adjusted life years gained will be estimated based on 6-month outcomes, including responses to the Euro-qol EQ5D questionnaire.

Finally, the implications of the trial for efficient provision of ECMO services in the UK will be considered. Until the end of the trial, ECMO will only be available in one centre. Cost analysis will be done to assess sensitivity of cost-effectiveness ratios to transport and local volume of service in the ICU and ECMO unit in order to predict the best configuration of ECMO services, if the treatment is effective.

**Data collection instruments for economic evaluation**

1) **For trial patients and relatives**
   a) Daily organ support chart to be completed by caregivers in intensive care units for each patient in trial
   b) Patient’s diary of events after discharge - to be completed and kept by patient to help answer questions at 6 months.
   c) EQ5D health related quality of life questionnaire (less than 5 minutes to complete)
   d) Patient’s and relative’s costs questionnaire: versions for survivors, and for relatives of patients who die (self completed)

2) **For participating centres**
   a) Costblock costing data - for each ICU (and equivalent for ECMO centre during final year of trial)
   b) Daily ward costs from participating hospitals (based on finance data)
   c) Transport costs

Other health and social care unit costs will be based on nationally available data (Netten and Dennett, PSSRU, University of Kent 1999) or special costing exercises by researchers.

**Sample size**

Based on the NIH ARDS network database we would anticipate 70% mortality in the control group. Cross-reference with the Case Mix Programme Database, which is the national comparative audit of patient outcomes co-ordinated by the Intensive Care National Audit & Research Centre (ICNARC) confirms that this estimated mortality is approximately correct. The mortality of the 1,506 patients with a PaO\textsubscript{2}/FIO\textsubscript{2} ratio of ≤100 mmHg in this database was 61.6%. The mean PaO\textsubscript{2}/FIO\textsubscript{2} ratio in the ECMO patients was 65 mmHg with an SD of 37. Thus our selection criteria of a Murray score of > 3.0 should successfully identify patients with an expected mortality of ≥ 70%. In addition this is also the patient group that is currently receiving ECMO. Assuming a 10% risk of severe disability among survivors in both trial arms, an alpha = 0.05 (2 sided test) and beta = 0.2, a sample size of 120 patients in each group (i.e. a total sample size of 240) would be required to detect a reduction in the rate of primary outcome from 73% to the 55% which is a conservative estimate based on the descriptive studies of adult ECMO already.
discussed. If the primary outcome rate in the control group was around 65% or more, a sample size of about 180 would be required to detect a reduction by about a third. As there is some controversy about the estimated mortality in the control group, we include a power calculation grid for a range of estimated mortalities (revised appendix 2), should data from the on-going trial suggest a different level.

**Recruitment rate**

Glenfield ECMO unit currently treats 40-50 adults per year. In 1997, 28 hospitals referred 44 patients for ECMO. If all 224 Intensive Care Units (ICUs) in the UK hospitals were to refer patients for ECMO at the same rate as the 28, a total of around 350 patients might be eligible for trial entry in the UK per annum. It is unlikely that all 224 centres will participate, so some patients will be treated in hospitals not participating in the trial, and some will not be asked for or give assent for the trial. If 100 centres do wish to take part, it should be possible to recruit 240 patients over a three year recruitment period. The recruitment rate will be at its maximum during the final year of recruitment when all 100 centres will be participating.

**Type of analysis**

Analysis will be by intention to treat, with sub-group analyses based on the minimisation criteria at trial entry.

**Frequency of analysis**

An independent Data Monitoring Committee (DMC) will review, in strict confidence, data from the trial approximately half way through the recruitment period. The Chair of the DMC may also request additional meetings/analyses. In the light of these data, and other evidence from relevant studies, the DMC will inform the Steering Committee, if in their view:

i) there is proof beyond reasonable doubt that the data indicate that any part of the protocol under investigation is either clearly indicated or contra-indicated, either for all patients or for a particular subgroup, or

ii) it is evident that no clear outcome will be obtained with the current trial design.

Unless modification or cessation of the protocol is recommended by the DMC, the Steering Committee, collaborators and administrative staff (except those who supply the confidential information) will remain ignorant of the results of the interim analysis.

**Membership of Data Monitoring Committee**

Professor Sir Richard Doll (chair)  
Professor Douglas Altman  
Professor Tim Evans  
Dr Duncan Macrae
Ethical considerations

Since the patients in this trial will all be sedated and ventilated the patient’s next of kin will be asked to give assent for the patient’s inclusion in the trial. There will be information booklets for the patient’s relatives which will include information about the trial, conventional treatment and ECMO. This may raise some ethical issues since strictly speaking the patient’s next of kin can only assent for treatment of an incompetent adult, and cannot give true consent on their behalf. However, we have a duty of care to act in the patient’s best interests and apply whatever treatment we believe to be the most effective. Since in this case it is not yet clear which treatment is most effective we have a larger duty of care to the community as a whole to determine which treatment is most effective by means of an RCT. When patients have recovered and been discharged home they will be informed that they have been part of a clinical trial and given a copy of the information leaflet. During the trial period it will not be possible to get adult respiratory ECMO in the UK except as part of the trial.

Ancillary studies

In addition to addressing the main aims of the study, some collaborators may wish to conduct other more detailed or complementary ancillary studies. The principal investigators welcome this provided that proposals are discussed in advance with the Trial Steering Committee.

Publication policy

To safeguard the scientific integrity of the trial, data from this study should not be presented in public or submitted for publication without requesting comments and receiving agreement from the Trial Steering Committee. The primary results of the trial will be published by the group as a whole without direct attribution of authorship, in the same way as the UK neonatal ECMO trial. The success of the trial depends on the collaboration of many people.

ORGANISATION

Principal investigators

i) Giles Peek: Will co-ordinate the activities of the collaborators at all clinical centres and the project staff at Glenfield Hospital Leicester, the Clinical Co-ordinating Centre, will organise the clinical advisory service and in conjunction with the clinical research fellow will promote the trial to encourage participation of referring centres. Will be closely involved in data analysis and a key member of the writing committee.

ii) Diana Elbourne: Will co-ordinate activity at the London School of Hygiene and Tropical Medicine (LSHTM), the Data Co-ordinating Centre with particular responsibility for data collection, management and statistics. Key member of writing committee, senior statistician.

iii) Richard Firmin: Will work closely with Giles Peek, will be head of the clinical advisory service. Will be involved in data analysis and a member of the writing committee.

iv) David Edbrooke: Will represent the conventional management centres and will be a key member of the economic study team and form part of the writing committee.
v) Ann Truesdale: Will work closely with Diana Elbourne as Study Co-ordinator working with staff at the LSHTM and form part of the writing committee.

vi) Miranda Mugford: Will co-ordinate the economic study team and work closely with David Edbrooke and Clare Hibbert, and form part of the writing committee.

vii) Hilliary Killer: Will assist in the day to day management of the trial at the ECMO centre and will work closely with the economic study team. Will form part of the clinical advisory team. Will provide a nursing and technical viewpoint.

viii) Clare Hibbert: Will be a member of the economic study team (with Miranda Mugford and David Edbrooke).

ix) Andy Wilson: Will co-ordinate the activities of the GP Advisory Group and take responsibility for the follow-up assessment at six months and form part of the writing committee.

Trial Steering Committee

The Steering Committee will approve the main study protocol, monitor and supervise the trial towards its interim and overall objectives, review relevant information from other sources, consider the recommendations of the DMC, and resolve problems brought by the trial co-ordinating centres. The committee will comprise an independent chairperson, Professor David Field, independent members Professor Nigel Webster (Professor of Anaesthesia and Intensive Care, Aberdeen Royal Infirmary), Professor Anne Tattersfield (Professor of Respiratory Medicine, Nottingham City Hospital), Wendy Nganasurian (Patients Association), Richard Adfield (Cruse Bereavement Care), Dr John Scott (East Anglian Ambulance Trust) as well as the members of the project management group. This represents all the different disciplines involved in the trial. Specialist working groups will advise the Steering Committee.

Project Management Group (PMG)

A project management group will be established and will be responsible for the day to day management of the trial. The group will comprise the principal investigators and project staff from the Clinical Co-ordinating Centre at Leicester and the Data Co-ordinating Centre at the LSHTM. The group will meet regularly in person and by telephone.

The responsibilities of the PMG include:
- Establishing and monitoring recruitment of participating centres
- Distribution and supply of data collection forms and other appropriate documentation for the trial
- Data collection and management
- Data entry and cleaning
- Data analysis
- Organising and servicing the Data Monitoring Committee

Local co-ordination

Each participating centre will identify an intensivist as a local co-ordinator and two intensive care nurses (one primary and one as backup).

The responsibility of the local co-ordinators will be to:
- Ensure local research ethics approval is obtained
- Be familiar with the trial and consider recruitment of potentially eligible patients
- Liaise with the Clinical Co-ordinating Centre to register eligible patients
- Liaise with the transport team when relevant
e) Liaise with the Data Co-ordinating Centre
f) Ensure that relevant medical and nursing staff are informed about the trial
g) Ensure that mechanisms for recruitment are in place
h) Ensure that data collection forms are completed and returned to the Data Co-ordinating Centre promptly and to deal with any queries
i) Facilitate other aspects of co-ordination as relevant
j) Make data available for verification, audit and inspection purposes as necessary
k) Liaise with the economics team
l) Ensure that the confidentiality of all information about trial participants is respected by all persons

Confidentiality

Patients will be identified by their trial number to ensure confidentiality. However, as the patients in the trial will be followed up to 6 months following randomisation, it is essential that the team at the Data Co-ordinating Centre has the names and addresses of the trial participants recorded on the data collection forms in addition to the allocated trial number. Stringent precautions will be taken to ensure confidentiality of names and addresses at the Data Co-ordinating Centre.

The investigators and local co-ordinators will ensure conservation of records in areas to which access is restricted.

Funding

The clinical treatment costs for patients in England are funded by the National Specialist Commissioning Advisory Group (NSCAG), as a supra-regional service. The costs for the study itself are covered by a grant from the Health Technology Assessment Programme (HTA). Clinical costs for patients in Wales will be covered by a reciprocal arrangement with NSCAG and the Welsh Department of Health. A similar arrangement is being negotiated for Scotland. Clinical costs for conventionally treated patients will be met by the NHS under existing contracts. If a conventional patient is not covered by an existing contract then their treatment will be funded under the Specialist Commissioning Service.
GLOSSARY

ARDS  Acute Respiratory Distress Syndrome
CTC  Conventional Treatment Centre
ECMO  Extra-corporeal Membrane Oxygenation
ECCO₂R  Extracorporeal Carbon Dioxide Removal
ELSO  Extracorporeal Life Support Organization
HTA  Health Technology Assessment
iNO  Inhaled Nitric Oxide
IPPV  Intermittent Positive Pressure Ventilation
ICU  Intensive Care Unit
NSCAG  National Specialist Commissioning Advisory Group
NIH  National Institute of Health (US)
PCIRV  Pressure Controlled Inverse Ratio Ventilation
PaO₂/FIO₂  Ratio between the oxygen tension in the arterial blood and the fraction of inspired oxygen
PEEP  Positive End Expiratory Pressure
PIP  Peak Inspiratory Pressure
RCT  Randomised Controlled Trial
RH  Referral Hospital
SERNIP  Safety and Efficiency Register of New Intervenional Procedures of the Medical Royal Colleges
TV  Tidal Volume
VV  Veno-venous


24 Thalanany M. Primary study to estimate the informal care costs of visiting patients in an adult intensive care unit. MSc Dissertation. University of Birmingham. 2002.


Appendix 1: Murray Score

The Murray score is a grading system for ARDS which uses 4 pieces of information graded 0-4 to give a severity index for ARDS. The data required are:

- $\text{PaO}_2/\text{FIO}_2$ in mmHg (multiply Kpa result x 7.5): this must be taken with the FIO2 at 1 for at least 20 minutes.
- $\text{PEEP}$ in CMH$_2$O
- Lung Compliance in ml/ CMH$_2$O
- Number of quadrants with infiltration seen on chest X-ray

Patients can be registered for the trial when the Murray Score exceeds 2.5, and are eligible to enter and be randomised when it exceeds 3.0. Patients who are hypercarbic, but not hypoxic and therefore have a low Murray score may enter the trial and be randomised once the arterial pH falls below 7.2 (give equivalent $[\text{H}^+]$). The Murray score is calculated by taking the score for each variable and dividing by 4, for the purposes of the CESAR trial all 4 variables must be used to calculate the score.

Score values

- $\text{PaO}_2/\text{FIO}_2$: $\geq 300=0, 225-299=1, 175-224=2, 100-174=3, <100=4$
- CXR: normal=0, 1 point per quadrant infiltrated.
- PEEP: $\leq 5=0, 6-8=1, 9-11=2, 12-14=3, \geq 15=4$.
- Compliance (ml/cmH$_2$O): $\geq 80=0, 60-79=1, 40-59=2, 20-39=3, \leq 19=4$

The compliance may be calculated as follows: \[ \frac{\text{TV}}{\text{PIP-PEEP}} \]

Example

- A patient has a $\text{PaO}_2$ of 6.6Kpa on 100% oxygen: To convert KPa to mmHg = 6.6 x 7.5 = 49.5 mmHg, divide by the FIO$_2$ (=1), the $\text{PaO}_2$/ FIO$_2$ is 49.5, as this is less than 100, score 4
- The Chest X-ray has consolidation and infiltration in 3 out of 4 quadrants score 3
- The PEEP is set at 10 CMH$_2$O, score 2
- The Peak airway pressure is 38 CMH$_2$O, and the tidal volume is 420 ml, PIP-PEEP = 28, compliance is $420/ 28 = 15$, score 4

The Murray score is (to one decimal place):

\[ 4 + 3 + 2 + 4 = 13, \]
\[ 13/ 4 = 3.3 \]

The Murray score is high enough for trial entry (>3)
APPENDIX 2: POWER CALCULATION GRID

Sample size calculation for different assumptions about mortality, disability and relative risk (\(\text{Beta} = 0.2, \text{Alpha} = 0.05, \text{2 sided}\))

<table>
<thead>
<tr>
<th>% of survivors severely disabled</th>
<th>Mortality in Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>70%</td>
</tr>
<tr>
<td>15%</td>
<td>15%</td>
</tr>
<tr>
<td>10%</td>
<td>15%</td>
</tr>
<tr>
<td>5%</td>
<td>15%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary adverse outcome %</th>
<th>74.5</th>
<th>73</th>
<th>71.5</th>
<th>66</th>
<th>64</th>
<th>62</th>
<th>57.5</th>
<th>55</th>
<th>52.5</th>
<th>53.25</th>
<th>50.5</th>
<th>47.75</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>64</td>
<td>66</td>
<td>70</td>
<td>82</td>
<td>86</td>
<td>92</td>
<td>104</td>
<td>112</td>
<td>122</td>
<td>118</td>
<td>128</td>
<td>140</td>
</tr>
<tr>
<td>Relative risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td>136</td>
<td>142</td>
<td>150</td>
<td>180</td>
<td>192</td>
<td>204</td>
<td>236</td>
<td>256</td>
<td>278</td>
<td>270</td>
<td>296</td>
<td>326</td>
</tr>
<tr>
<td>0.67</td>
<td>224</td>
<td>236</td>
<td>250</td>
<td>302</td>
<td>324</td>
<td>348</td>
<td>404</td>
<td>440</td>
<td>480</td>
<td>468</td>
<td>514</td>
<td>566</td>
</tr>
<tr>
<td>0.75</td>
<td>336</td>
<td>356</td>
<td>378</td>
<td>462</td>
<td>496</td>
<td>532</td>
<td>624</td>
<td>682</td>
<td>746</td>
<td>726</td>
<td>800</td>
<td>62</td>
</tr>
<tr>
<td>0.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


The sample size was reviewed June 2003 when the Principal Investigators made an application for an extension of funding to the HTA. In the original application, they provided a grid showing the implications of different estimates for the primary outcome in the control group and for the size of difference. This showed, for instance, that with a sample size of about 240 if the primary outcome rate in the control group was about 57% or more they would be able to detect a reduction by a third OR if the primary outcome rate in the control group was about 73% or more, they would be able to detect a reduction by a quarter. If the primary outcome rate in the control group was around 65% or more, a sample size of about 180 would allow them to detect a reduction by a third (all estimates based on 5% statistical significance (2-sided test) and 80% power). The HTA agreed an extension of recruitment to the end of November 2005 by which time CESAR is likely to recruit about 180 patients.